AI Article Synopsis
- The study investigated cystathionine levels in blood and urine of early-stage Huntington disease (HD) patients compared to controls.
- Despite the initial hypothesis, the results showed no significant differences in cystathionine or other amino acids between the two groups.
- The conclusion suggests that cystathionine levels do not serve as a reliable biomarker for assessing the progression of HD in early stages.
Article Abstract
Background: Recently a profound depletion of cystathionine γ-lyase (CSE), the principal enzyme involved in the generation of cysteine from cystathionine, was shown in Huntington disease (HD) patients and several transgenic HD mouse models. We therefore hypothesized that blood and urine cystathionine levels may be increased in HD patients and that this increase might correlate with disease progression.
Methods: We measured concentrations of cystathionine as well as 22 other amino acids in fasting plasma and 24-h urine samples of nine early-stage HD patients and nine age, sex, and body mass index matched controls.
Results: There were no significant differences in the plasma or urine concentrations of cystathionine or any other amino acid between HD patients and controls.
Conclusion: We found no evidence for changes in plasma or urine concentrations of cystathionine in early-stage HD patients. Therefore, cystathionine levels are unlikely to be useful as a state biomarker in HD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582017 | PMC |
| http://dx.doi.org/10.1371/currents.hd.c63b441d04bb6738c0234f91c2b3e312 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!